Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and children aged 9 years and older.

Accropeutics’ oral, selective TYK2/JAK1 inhibitor AC-201 has met the primary and key secondary endpoints in a Phase II ...

The dosing interval for ixekizumab may be extended in some patients with plaque psoriasis, and switching between biologics ...

Guselkumab treatment was associated with improvements in 3 biomarkers associated with systemic inflammation among patients with plaque psoriasis.

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis, according to results from the ICONIC-TOTAL study.

Icotrokinra demonstrated high rates of clearance in scalp and genital psoriasis after 16 weeks of treatment, according to ...

Let’s discuss four foods to avoid with psoriasis that may be affecting your skin, along with healthier substitutes.

The company noted that among adults and adolescents with at least moderate plaque psoriasis in high-impact ... 66 percent achieved clear or almost clear scalp, and 77 percent reached minimal ...

evaluated the safety and efficacy of icotrokinra in 311 adults and adolescents 12 years of age and older with plaque psoriasis affecting the scalp, genital area, and/or palms of the hands and ...